<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970538</url>
  </required_header>
  <id_info>
    <org_study_id>LF-CA-PR-3</org_study_id>
    <nct_id>NCT03970538</nct_id>
  </id_info>
  <brief_title>The PROMISE II Trial, Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia</brief_title>
  <acronym>PROMISE</acronym>
  <official_title>Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia: the PROMISE II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LimFlow, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LimFlow, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LimFlow System is intended for endovascular, minimally invasive procedures in patients
      who have a clinical diagnosis of chronic limb-threatening ischemia and who have been
      determined to have no surgical or endovascular treatment option (i.e., &quot;no option&quot;).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this US pivotal trial is to investigate the safety and effectiveness of The
      LimFlow System for creating an AV connection in the Below The Knee (BTK) vascular system
      using an endovascular, minimally invasive approach to arterialize the pedal veins for the
      treatment of chronic limb-threatening ischemia (CLTI) in subjects ineligible for conventional
      endovascular or surgical limb salvage procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center pivotal study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amputation Free Survival (AFS)</measure>
    <time_frame>6 months post-procedure</time_frame>
    <description>freedom from major amputation and death at 6 months, compared to a historical performance goal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>30 days and 6 months post-procedure</time_frame>
    <description>Absence of occlusion of the endovascular intervention that is maintained without the need for additional or secondary surgical or endovascular procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary Assisted Patency</measure>
    <time_frame>30 days and 6 months post-procedure</time_frame>
    <description>Absence of occlusion of the endovascular intervention maintained with the use of additional or secondary surgical or endovascular procedures, as long as occlusion of the primary treated site has not occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency</measure>
    <time_frame>30 days and 6 months post-procedure</time_frame>
    <description>Absence of occlusion of the endovascular intervention that is maintained with the use of additional or secondary surgical endovascular procedures after occlusion occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limb Salvage</measure>
    <time_frame>30 days, 3 and 6 months post-procedure</time_frame>
    <description>The percentage of subjects with freedom from above-ankle amputation of the index limb.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Classification</measure>
    <time_frame>30 days, 3 and 6 months post-procedure</time_frame>
    <description>A change of one Rutherford class or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Immediately post-procedure</time_frame>
    <description>Successful placement of the arterial and venous catheters in the desired location in the limb, ability to place the stent grafts, completion of the endovascular procedure, and immediate morphological success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>30 days post-procedure</time_frame>
    <description>Combination of Technical Success, and absence of all-cause death, above-ankle amputation or clinically driven major re-intervention of the stent graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Wound Healing</measure>
    <time_frame>30 days, 3, 6, 9, and 12 months post-procedure</time_frame>
    <description>Complete healing of the patient's target wound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Wound Healing</measure>
    <time_frame>30 days, 3, 6, 9, and 12 months post-procedure</time_frame>
    <description>Complete healing of the patient's wounds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Contrast-Induced Nephropathy</measure>
    <time_frame>Within the first 72 hours post-procedure</time_frame>
    <description>Subjects without acute (within 72 hours after intravenous contrast administration) impairment of renal function, measured as an absolute ≥0.5 mg/dL (44 µmol/L) increase compared to baseline SCr value that results in a value above the upper limit of the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>Immediately post-procedure</time_frame>
    <description>Time from the first puncture (venous or arterial) to when the last catheter is removed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Exposure</measure>
    <time_frame>During the procedure</time_frame>
    <description>Patient radiation exposure (measured in milligray)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Volume</measure>
    <time_frame>During the procedure</time_frame>
    <description>Total volume of contrast media (measured in milliliters)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Critical Lower Limb Ischemia</condition>
  <condition>Peripheral Artery Disease</condition>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Chronic Limb-Threatening Ischemia</condition>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Arterial Occlusion</condition>
  <condition>Arterial Disease</condition>
  <condition>Peripheral Artery Occlusion</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Peripheral Ischemia</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with the LimFlow System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LimFlow System</intervention_name>
    <description>Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be ≥18 and ≤ 95 years of age

          2. Clinical diagnosis of chronic limb-threatening ischemia, defined as any of the
             following clinical assessments: previous angiogram or hemodynamic evidence of severely
             diminished arterial inflow of the index limb (e.g., ABI ≤ 0.39, TP / TcPO2 &lt; 30 mm Hg)
             and

               1. Rutherford Classification 5, ischemic ulceration or

               2. Rutherford Classification 6, ischemic gangrene

          3. Subject has been assessed by the principal investigator, reviewed by the Independent
             Review Committee (IRC), and determined that no conventional distal bypass surgical or
             endovascular therapy for limb salvage is feasible due to either a) absence of a usable
             pedal artery target (endovascular or surgical approach), or b) the presence of a pedal
             artery target with absence of a viable single-segment vein in either lower extremity
             or either arm that could be used for autogenous vein conduit.

          4. Proximally, the Target In-flow Artery at the cross-over point must fall within the
             recommended vessel diameter ranges for the LimFlow stent graft by visual estimation.

          5. Prior stent(s) to the infrainguinal arteries (e.g. iliac, SFA, and popliteal) are
             allowed.

          6. Planned minor amputation (e.g. partial toe, ray or proximal foot/transmetatarsal) of
             target extremity within 30 days after the index procedure is allowed.

          7. Subject is willing and able to sign the informed consent form.

          8. Subject is enrolled in an acceptable wound care network and has an adequate support
             network to ensure that subject is compliant with medication regimen and follow-up
             study visits.

          9. Prior to enrollment (7-day window), women of childbearing potential must have a
             negative pregnancy test.

         10. Primary wound is stable (e.g. not rapidly deteriorating and/or showing signs of
             healing)

         11. Stable glycemic control, HbA1C &lt; 10% (&lt;269mg/dL)

         12. Subjects requiring dialysis may be included, provided they meet all the following
             requirements:

               -  On dialysis for &gt; 6 months

               -  Autologous arteriovenous (AV) fistula access used for hemodialysis

               -  Serum albumin &gt; 30 g/liter

               -  BMI &gt; 20

        Exclusion Criteria:

          1. Subjects will be excluded from participating in this study if they meet any of the
             following criteria prior to initiation of the endovascular procedure: Concomitant
             hepatic insufficiency, thrombophlebitis in the target limb, or non-treatable
             coagulation disorder within the past 90 days.

          2. Active immunodeficiency disorder or currently receiving immunosuppressant therapy for
             an immunodeficiency disorder.

          3. Prior peripheral arterial bypass procedure above or below the knee which would inhibit
             proximal inflow to the stent graft or interventional revascularization procedure
             within 30 days.

          4. Previous major amputation of the target limb or presence of a wound requiring a free
             flap.

          5. Life expectancy less than 12 months.

          6. Documented myocardial infarction or stroke within previous 90 days.

          7. Active infection (e.g. fever, significantly elevated WBC count &gt;20.0 x 109/L, and/or
             positive blood culture) at the time of the index procedure that may preclude insertion
             of a prosthesis or require major amputation (e.g. osteomyelitis proximal to
             metatarsals).

          8. Known or suspected allergies or contraindications to aspirin or P2Y12 inhibitors,
             heparin, stainless steel, nitinol or contrast agent that cannot be adequately
             pre-treated.

          9. Subject is currently taking anti-coagulants, which in the opinion of the investigator,
             interferes with the subject's ability to participate in the study (i.e., intermittent
             interruption of therapy for procedure may compromise subject's safety).

         10. Lower extremity vascular disease that may inhibit the procedure and/or jeopardize
             wound healing (e.g. vasculitis, Buerger's disease, significant edema in the target
             limb, deep venous thrombus in the target vein, hyperpigmentation, or medial ulceration
             above the ankle).

         11. Significant acute or chronic kidney disease with a serum creatinine of &gt; 2.5 mg/dl in
             subjects not undergoing dialysis.

         12. Severe heart failure (e.g. NYHA Class IV), which in the opinion of the investigator
             may compromise subject's ability to safely undergo a percutaneous procedure.

         13. Any significant concurrent medical, psychological, or social condition, which may
             significantly interfere with the subject's optimal participation in the study, in the
             opinion of the investigator.

         14. The subject is currently participating in another investigational drug or device study
             that has not completed the primary endpoint or that clinically interferes with the
             endpoints of this study.

         15. Subject is unwilling or unable to comply with any of the protocol or follow-up
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>94 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Clair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prisma Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Engels</last_name>
    <phone>888-478-7705</phone>
    <phone_ext>101</phone_ext>
    <email>Tengels@limflow.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia Petrella</last_name>
    <phone>3342024307</phone>
    <email>cpetrella@limflow.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rowena Buwalda</last_name>
      <email>rbuwalda@dhs.lacounty.gov</email>
    </contact>
    <investigator>
      <last_name>Mark Archie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cardiac and Vascular Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Knight</last_name>
      <phone>352-375-1212</phone>
      <phone_ext>1324</phone_ext>
      <email>sknight@tcavi.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>Kenner</city>
        <state>Louisiana</state>
        <zip>70065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Pellegrin</last_name>
      <phone>504-842-2690</phone>
      <email>mopellegrin@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Zola N'Dandu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ogheneyoma Akpoviroro, MUDr</last_name>
      <phone>617-414-6832</phone>
      <email>Ogheneyoma.Akpoviroro@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Alik Farber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Aarnio</last_name>
      <phone>603-650-7966</phone>
      <email>Wendy.H.Aarnio@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Richard Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaritza M De Los Santos</last_name>
      <phone>704-355-4713</phone>
      <email>Yaritza.DeLosSantos@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Gregory Stanley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>George Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Surgical Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Helm, PA</last_name>
      <phone>910-343-0811</phone>
      <email>thelm@coastalsurgery.com</email>
    </contact>
    <investigator>
      <last_name>David Weatherford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Zeuli</last_name>
      <phone>216-844-3545</phone>
      <email>maria.zeuli@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Mehdi Shishehbor, DO, MPH, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health -- Midlands</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Sholts</last_name>
      <phone>803-434-8262</phone>
      <email>jennifer.sholts@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Clair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health -- Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosie Gaddy</last_name>
      <phone>864-454-2808</phone>
      <email>Rosie.gaddy@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Bruce Gray, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Shahbazi</last_name>
      <phone>713-798-3023</phone>
      <email>Mohammad.Shahbazi@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Mills, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Montero-Baker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School</name>
      <address>
        <city>Ponce</city>
        <zip>00731</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Echevarría Báez</last_name>
      <phone>787-840-2575</phone>
      <phone_ext>5662</phone_ext>
      <email>Jesechevarria@psm.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge Martinez-Trabal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLI</keyword>
  <keyword>CLTI</keyword>
  <keyword>Amputation</keyword>
  <keyword>Desert Foot</keyword>
  <keyword>PAD</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Critical Limb Ischemia</keyword>
  <keyword>Chronic Limb-Threatening Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

